Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients

Vasc Health Risk Manag. 2020 Apr 1:16:103-110. doi: 10.2147/VHRM.S240500. eCollection 2020.

Abstract

Background: The aim was to evaluate factor XIII activity (FXIIIa) and monocyte-derived microparticles (MDMPs) in cancer patients.

Methods: In total, 138 cancer patients (31 malignant lymphomas, 39 multiple myelomas, and 68 lung cancers) were analyzed. We measured various biomarkers including FXIIIa and MDMPs.

Results: The values of endothelial activation markers, monocyte chemoattractant peptide (MCP)-1, soluble (s)CD14, and MDMPs were higher in cancer patients than in non-cancerous controls. MCP-1, sCD14, and MDMPs were significantly correlated with FXIIIa in multivariate analysis in cancer patients. In addition, MCP-1, sCD14, and MDMP levels were significantly increased in the high FXIIIa group of patients. Finally, the survival rate of the high FXIIIa group was significantly poor in the Kaplan-Meier analysis.

Conclusion: These results suggest that abnormal levels of FXIIIa and MDMPs may offer promise as poor prognostic factors in cancer patients.

Keywords: MDMP; cancer; endothelial cell; factor XIII activity; monocyte-derived microparticle; thrombosis.

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • Case-Control Studies
  • Cell-Derived Microparticles / metabolism*
  • Factor XIII / metabolism*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Monocytes / metabolism*
  • Neoplasms / blood*
  • Neoplasms / complications
  • Neoplasms / diagnosis
  • Thrombosis / blood*
  • Thrombosis / diagnosis
  • Thrombosis / etiology

Substances

  • Biomarkers
  • Factor XIII